newsfilter
← Latest News
GlobeNewswire·

AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

– On track to commence Phase 2 study for lead program evaluating Ampligen® (rintatolimod) for the treatment of pancreatic cancer in Q3 2022 – Well-positioned to achieve multiple near-term clinical and regulatory value-driving mileston